Company Filing History:
1 out of 2,405 
1 out of 47 Years Active: 2010
Title: David Bramhill: Innovator in HIV Research
Introduction
David Bramhill is a notable inventor based in Westfield, NJ (US). He has made significant contributions to the field of antiviral research, particularly in the development of innovative peptides aimed at combating HIV. His work has the potential to impact therapeutic strategies against this challenging virus.
Latest Patents
David Bramhill holds a patent for "Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity." This patent describes methods for covalently stabilizing alpha-helical, chimeric peptides within a coiled-coil structure. The coiled-coil structures mimic the internal trimeric coiled-coil motif found in the fusogenic conformation of enveloped virus membrane-fusion proteins, specifically the HIV gp41 ectodomain. The chimeric peptides he developed are designed to inhibit HIV infectivity by preventing the virus from fusing with host cell membranes.
Career Highlights
Throughout his career, David Bramhill has worked with prominent organizations, including Merck Sharp & Dohme Corporation and Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa. His experience in these institutions has contributed to his expertise in the field of molecular biology and antiviral research.
Collaborations
David has collaborated with esteemed colleagues such as Elisabetta Bianchi and Antonello Pessi. These partnerships have furthered his research and development efforts in the fight against HIV.
Conclusion
David Bramhill's innovative work in developing antiviral peptides represents a significant advancement in HIV research. His contributions may lead to new therapeutic options for those affected by this virus.